Although IM revolutionized the treatment of unresectable or metastatic GIST with primary KIT and PDGFRA mutations, prolonged IM treatment is required to prevent the re-activation of quiescent nonproliferating tumor cells, since IM is cytostatic and not cytocidal. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.